Next-generation Sequencing: Emerging Clinical Applications and Global Markets

Published - Jun 2017| Analyst - John Bergin| Code - BIO126C
Next-generation Sequencing: Emerging Clinical Applications and Global Markets
Single User License: $5500 Member Price: FREE

Report Highlights

The global clinical next-generation sequencing (NGS) market reached $2.7 billion in 2016. This market is expected to grow at a compound annual growth rate (CAGR) of 27%, from nearly $3.2 billion in 2017 to $10.5 billion by 2022.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications.
  • Analyses of global market trends, with data from 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Examination of the sequencing industry structure for key market segments.
  • Discussion covering the strategies employed by the main companies in the market.
  • Comprehensive company profiles of major players in the field.

Report Scope

The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2015, 2016, 2017 and 2022.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the significant research initiatives that impact clinical NGS applications. The main market driving forces are also discussed.

The report examines the markets by test complexity, clinical indication and test purpose. Test complexity refers to the plex level (i.e., the number of genetic markers that can be analyzed within a sample) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics, etc.) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, cardiovascular diseases, clinical microbiology and infectious diseases, Mendelian disorders, metabolic and immune disorders, neurological disorders, reproductive health, and transplant medicine.

Specific geographic markets are discussed, including North America, Europe, Asia-Pacific, and the rest of the world.

Industry sectors analyzed include sequencing instruments, target enrichment, informatics, clinical laboratory testing services, reproductive health diagnostics, liquid biopsy, immune sequencing, HLA typing, third generation sequencing, and direct to consumer.

More than 200 companies in the clinical NGS industry are profiled in this report.

BCC Research provides a summary of the main industry acquisitions and strategic alliances from 2015 through April 2017, including key alliance trends.

Analyst Credentials

John Bergin has held business development, sales and marketing positions with a Fortune 500 advanced materials company, as well as executive management positions with a nanotechnology/separations company. Bergin holds a B.S. degree in Chemistry, an M.S. degree in Biotechnology and a Master of Business Administration. John Bergin is a pseudonym of the author.

Select reports include:

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
 
Published - Jun-2015| Analyst - John Bergin| Code - BIO126B

Report Highlights

The global clinical next-generation sequencing (NGS) market was valued at $886.1 million in 2014. This market is expected to grow at a compound annual growth rate (CAGR) of 31.3%, from $997.1 million in 2015 to nearly $3.9 billion by 2020.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications.
  • Analyses of global market trends, with data from 2014, estimates for 2015, and projections of CAGRs through 2020.
  • Examination of the sequencing industry structure for key market segments.
  • Discussion covering the strategies employed by the main companies in the market.
  • Comprehensive company profiles of major players in the field.
Published - Jul-2013| Analyst - John Bergin| Code - BIO126A

Report Highlights

The next generation sequencing market reached $231.7 million in 2012. The market is expected to reach $510.7 million in 2013 and $7.6 billion in 2018 for a compound annual growth rate (CAGR) of 71.6%.

Report Includes

  • An overview of the global market for next-generation sequencing and its emerging clinical applications
  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  • Examination of the sequencing industry structure for the key market segments, as well as strategic alliances and acquisitions, as well as evaluations of sequencing patents
  • Discussion of the strategies of the main companies in the market
  • Comprehensive company profiles of major players in the field
CUSTOM RESEARCH

Need a custom data table, graph or complete report? Tell us more.

Contact Us
RELATED REPORTS
Share This Report